About My Health Careers Internship MedBlogs Contact us

New Antibiotic Shows Similar Effectiveness For Treating Skin Infection

by Sheela Philomena on February 13, 2013 at 11:06 AM
Font : A-A+

 New Antibiotic Shows Similar Effectiveness For Treating Skin Infection

In patients with acute bacterial skin and skin structure infections, treatment with new antibiotic tedizolid phosphate was no worse than in efficacy to the antibiotic linezolid, say researchers.

"Antimicrobials available for treatment of complicated skin and skin structure infections (SSSIs) are generally efficacious, but antimicrobial resistance and adverse effects limit their use. Linezolid, an oxazolidinone [a class of antibiotics], is the only oral drug approved for complicated SSSI caused by methicillin-resistant Staphylococcus aureus (MRSA)," according to background information in the article. Sporadic outbreaks of linezolid-resistant strains of MRSA have been reported. Acute bacterial skin and skin structure infections (ABSSSIs) can be life-threatening and may require surgery and hospitalization. "Increasingly, ABSSSIs are associated with drug-resistant pathogens, and many antimicrobial agents have adverse effects restricting their use. Tedizolid phosphate is a novel oxazolidinone in development for the treatment of ABSSSIs."


Philippe Prokocimer, M.D., of Trius Therapeutics Inc., San Diego, and colleagues conducted a study to establish the noninferiority of tedizolid phosphate vs. linezolid in treating ABSSSIs and compare the safety of the 2 agents. The phase 3, randomized trial was conducted from August 2010 through September 2011 at 81 study centers in North America, Latin America, and Europe. The intent-to-treat analysis set consisted of data from 667 adults ages 18 years or older with ABSSSIs treated with tedizolid phosphate (n = 332) or linezolid (n = 335). Patients were randomized to a 200 mg once daily dose of oral tedizolid phosphate for 6 days or 600 mg of oral linezolid every 12 hours for 10 days. The primary efficacy outcome was early clinical response at the 48- to 72-hour assessment (no increase in lesion surface area from baseline and oral temperature of 99.7°F or less, confirmed by a second temperature measurement within 24 hours). A 10 percent noninferiority margin was predefined.

The researchers found in the primary efficacy intent-to-treat (ITT) analysis, the response rates at the 48- to 72-hour assessment were 79.5 percent of 332 patients in the tedizolid phosphate group and 79.4 percent of 335 patients in the linezolid group. Sustained clinical treatment response rates at the end of treatment (day 11) were similar in the tedizolid phosphate and linezolid groups in the ITT analysis set (69.3 percent vs. 71.9 percent, respectively). Investigator-assessed clinical treatment response at the post-therapy evaluation (PTE) visit was also similar in the tedizolid phosphate and linezolid groups in the ITT analysis set (85.5 percent vs. 86.0 percent, respectively).

"Of particular interest are the similar treatment response rates in the tedizolid phosphate group (78.0 percent) and in the linezolid group (76.1 percent) in the sensitivity analysis that was based on the Foundation for the National Institutes of Health recommended outcome (≥ 20 percent decrease in lesion area)," the authors write.

Also, the researchers found that the clinical response rate at the PTE (7 to 14 days after completing therapy) was high (85 percent) for 178 patients infected with MRSA and similar in both the tedizolid phosphate and linezolid treatment groups.

Treatment-emergent adverse events (mostly mild or moderate) occurred in 40.8 percent of patients in the tedizolid phosphate group and 43.3 percent of patients in the linezolid group. The overall incidence of serious adverse events was low and similar between groups.

"A short course of tedizolid phosphate was statistically noninferior to a 10-day course of linezolid for both early and sustained clinical responses in patients with ABSSSIs. Results were consistent for primary and sensitivity analyses, using either objective criteria or investigators' assessments, and treatment response rates were concordant for early and late time points," the authors conclude.
(JAMA. 2013;309(6):559-569; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Trius Therapeutics funded and conducted the trial. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.

Antibiotics for Skin Infections - New Study Design and a Step Toward Shorter Course Therapy

Shira Doron, M.D., and Helen W. Boucher, M.D., of Tufts Medical Center and Tufts University School of Medicine, Boston, comment on the findings of this study in an accompanying editorial.

"In the study by Prokocimer et al, only 2.4 percent of those who responded to treatment at the 48- to 72-hour assessment in the tedizolid group and 2 percent of those in the linezolid group experienced treatment failure at later time points, and only 7.2 percent and 8 percent, respectively, of the early nonresponders to treatment successfully responded to treatment at the later time point. This notable correlation between the early and late end points suggests that either is appropriate for noninferiority antibiotic trials. However, broad conclusions should not be drawn from this single study; future studies are needed to further enlighten the choice of end points."

"Tedizolid is a new oral antibiotic that appears efficacious using a short course and may have a better safety profile than linezolid. The current study brings the Infectious Diseases Society of America's 10 X 20 initiative 1 step closer to its goal of regulatory approval of 10 new antibacterial drugs with activity against drug-resistant bacteria by 2020. If approved, tedizolid will be the first oral drug in this initiative. [This study] also takes an important step toward validating the feasibility of implementing the new FDA end points for ABSSSI. Future studies should add to the understanding of which patients may be treated safely with shorter-course therapy and further explore the correlation between early and sustained response in ABSSSI."

Source: Newswise

News A-Z
News Category
What's New on Medindia
Cochlear Implants may Consequently Drive Hearing Loss
E-cigarettes Use Linked to Erectile Dysfunction
Memory Loss - Can it be Recovered?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Boils / Skin Abscess Pityriasis rosea Flu Pemphigus Hives Scleroderma MRSA - The Super Bug Drug Resistance - Antibiotic Resistance Vitiligo Skin Self Examination 

Recommended Reading
Boils - Treatment by Drugs
Diabetes patients have reduced immunity, which makes them more susceptible to skin infections like ....
Skin Disorder
Skin types can range from oily to dry, extreme dryness accompanied by rashes and itching can often ....
Sunlight Reduces the Risk of Developing Skin Infections
Sunlight can help reduce the risk of developing skin allergies, a recent research has revealed....
Do Not Take Antibiotics for Cough, as an Average One Lasts About Three Weeks
This piece of advice is applicable for those who are worried about a nagging cough. Though, it is .....
Drug Resistance - Antibiotic Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and ...
Hives or Urticaria are allergic skin reaction that appear suddenly in clusters or as single bumps on...
MRSA - The Super Bug
MRSA infection is the most dreaded hospital or community acquired infection that can become ......
Pemphigus is a rare group of autoimmune diseases that affect the skin and mucous membranes causing b...
Pityriasis Rosea
Pityriasis rosea is a common skin disease that is not contagious. It manifests as oval-shaped, pink ...
Scleroderma or CREST syndrome is a chronic, auto immune disease which manifests as thick, dry, fibro...
Skin Self Examination
The skin self examination means checking ones own skin for any visible abnormal growths or unusual ...
Vitiligo is a skin disease characterized by patches of unpigmented skin. Vitiligo is usually slowly ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use